

Table SI. Outcome and process attributes and attribute levels included in the discrete choice experiment

	Attribute level
<i>Outcome</i>	
Overall response rate (ORR), %	10–25 25–40 40–55 55–70
2-year survival rate, %	20–40 40–50 50–60 60–70
Progression-free survival (PFS), months	2–4 5–7 8–10 11–13
Time to response, weeks	<4 4–8 8–12 12–16
Type of adverse events	Autoimmune disorders that could affect, e.g. thyroid gland, bowel or liver Rash, photosensitivity reaction and warty hyperkeratosis Pyrexia, chills and flu-like symptoms Diarrhoea, nausea and decreased appetite
Probability of adverse event-related treatment discontinuation, %	3–10 10–20 20–30 30–40
<i>Process</i>	
Route of administration	4–6 tablets per day 6–12 tablets per day Infusions, administered by a physician Injections into the tumour tissue, administered by a physician
Frequency of administration	Once daily Twice daily Every 2 weeks Every 3 weeks
Frequency of consultations	Once a week Every 2 weeks Every 3 weeks Every 4 weeks